Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.28 USD
Change Today +0.09 / 2.82%
Volume 460.0
CLRB On Other Exchanges
Symbol
Exchange
NASDAQ CM
Berlin
As of 5:20 PM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

cellectar biosciences inc (CLRB) Snapshot

Open
$3.11
Previous Close
$3.19
Day High
$3.28
Day Low
$3.11
52 Week High
08/4/14 - $6.64
52 Week Low
10/20/14 - $1.76
Market Cap
24.8M
Average Volume 10 Days
10.2K
EPS TTM
$-1.83
Shares Outstanding
7.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CELLECTAR BIOSCIENCES INC (CLRB)

Related News

No related news articles were found.

cellectar biosciences inc (CLRB) Related Businessweek News

No Related Businessweek News Found

cellectar biosciences inc (CLRB) Details

Cellectar Biosciences, Inc., a biopharmaceutical company, develops compounds for the treatment, diagnosis, and imaging of cancer. The company’s proprietary product candidates include I-124-CLR1404, a small-molecule, broad-spectrum, and cancer-targeting positron emission tomography (PET) imaging agent that is in Phase II clinical trial for glioblastoma, as well as in Phase I/II clinical trials for approximately 11 solid tumor indications; and CLR1502, a preclinical, cancer-targeted, and non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. It also develops I-131-CLR1404, a small-molecule, broad-spectrum, and cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells, as well as completed Phase Ib dose-escalation trial for patients with advanced solid tumors. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.

cellectar biosciences inc (CLRB) Top Compensated Officers

Founder, Chief Scientific Officer and Directo...
Total Annual Compensation: $180.3K
Chief Financial Officer, Vice President and T...
Total Annual Compensation: $127.9K
Vice President of Investor Relations, Public ...
Total Annual Compensation: $225.0K
Compensation as of Fiscal Year 2014.

cellectar biosciences inc (CLRB) Key Developments

Cellectar Biosciences, Inc. Announces Resignation of Kathryn McNeil as Vice President of Investor Relations, Public Relations and Corporate Communications

On July 28, 2015, Kathryn McNeil, Cellectar Biosciences, Inc.'s Vice President of Investor Relations, Public Relations and Corporate Communications, tendered her resignation which was accepted by the company and her position was eliminated.

Cellectar Biosciences, Inc. Announces Board Changes

On July 1, 2015, the board of directors of Cellectar Biosciences, Inc. elected Paul Berns as Chairman of the board, replacing Dr. Stephen Hill, who had served in that role since September 2007. Additionally, the board of directors elected Dr. Stefan Loren as Chairman of the Nominating and Corporate Governance Committee, and as a member of the Audit Committee, replacing Paul Berns in both of those roles.

Cellectar Biosciences, Inc. Announces Management Changes

Cellectar Biosciences, Inc. announced that James V. Caruso was appointed as president and chief executive officer, replacing Dr. Simon Pedder who has retired due to personal family reasons. Mr. Caruso was also named to Cellectar's Board as a Director. Mr. Caruso, 56, brings more than 25 years of industry experience to the role, having served most recently as executive vice president, chief operating officer and co-founder of HIP Innovation Technology, LLC. He previously held positions as executive vice president, chief commercial officer at Allos Therapeutics, senior V.P., sales and marketing at Bone Care International, as well as a variety of sales and marketing leadership positions at Novartis, Bristol Myers-Squibb and BASF. Dr. Simon Pedder has resigned as CEO and president, and as a director of Cellectar, and will retire from full-time employment. Cellectar also announced the appointment of Stefan Loren, Ph.D. as an independent Director. Dr. Loren, 51, is the founder of Loren Capital Strategy (LCS). Prior to LCS, Dr. Loren held the position of managing director at Westwicke Partners, developing and executing capital markets, business development and investor relations strategies. He is currently a director at GenVec and Marina Biosciences.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLRB:US $3.28 USD +0.09

CLRB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLRB.
View Industry Companies
 

Industry Analysis

CLRB

Industry Average

Valuation CLRB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLECTAR BIOSCIENCES INC, please visit www.cellectar.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.